Skip to content

Study · Animal study (in vivo) · rat · 2013

9 results

Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury.

van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, Ottens PJ, Ploeg RJ, Leuvenink HG

Journal of translational medicine13 Nov 2013Cited by 15 (Europe PMC)

PMID24225194 (opens in a new tab)PMCIDPMC3842642 (opens in a new tab)DOI10.1186/1479-5876-11-286 (opens in a new tab)PepBankPUB-24225194
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

BackgroundARA290 is a non-erythropoietic EPO derivative which only binds to the cytoprotective receptor complex (EPOR2-βcR2) consisting of two EPO-receptors (EPOR) and two β common receptors (βcR). ARA290 is renoprotective in renal ischemia/reperfusion (I/R). In a renal I/R model we focussed on timing of post-reperfusional administration of ARA290. Furthermore, we investigated the anti-inflammatory properties of ARA290.MethodsTwenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment. Rats were sacrificed after three days.ResultsEarly ARA290 treatment improved renal function. Late- or repetitive treatment tended to improve clinical markers. Furthermore, early ARA290 treatment reduced renal inflammation and acute kidney injury at three days post-reperfusion. Late- or repetitive treatment did not affect inflammation or acute kidney injury.ConclusionsARA290 attenuated renal ischemia/reperfusion injury. This study showed the anti-inflammatory effect of ARA290 and suggests early administration in the post-reperfusional phase is most effective. ARA290 is a candidate drug for protection against ischemic injury following renal transplantation.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with renal ischemia/reperfusion, early ARA290 treatment improved renal function.

    In plain wordsIn rats with kidney injury, ARA290 given early improved kidney function, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Direction not reportedRenal function, early treatment (one hour post-reperfusion)
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Early ARA290 treatment improved renal function.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with renal ischemia/reperfusion, late ARA290 treatment tended to improve clinical markers (a trend).

    In plain wordsIn rats with kidney injury, ARA290 given late showed only a trend toward better kidney markers, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeClinical markers of renal function, late treatment (four hours post-reperfusion)
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Late- or repetitive treatment tended to improve clinical markers.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with renal ischemia/reperfusion, repetitive ARA290 treatment tended to improve clinical markers (a trend).

    In plain wordsIn rats with kidney injury, repeated ARA290 doses showed only a trend toward better kidney markers, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeClinical markers of renal function, repetitive treatment (one and four hours post-reperfusion)
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Late- or repetitive treatment tended to improve clinical markers.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with renal ischemia/reperfusion, early ARA290 treatment reduced renal inflammation at three days post-reperfusion.

    In plain wordsIn rats with kidney injury, ARA290 given early reduced kidney inflammation at three days, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseRenal inflammation, early treatment
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, early ARA290 treatment reduced renal inflammation and acute kidney injury at three days post-reperfusion.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with renal ischemia/reperfusion, early ARA290 treatment reduced acute kidney injury at three days post-reperfusion.

    In plain wordsIn rats with kidney injury, ARA290 given early reduced acute kidney damage at three days, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseAcute kidney injury, early treatment
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, early ARA290 treatment reduced renal inflammation and acute kidney injury at three days post-reperfusion.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats with renal ischemia/reperfusion, late ARA290 treatment did not affect inflammation.

    In plain wordsIn rats with kidney injury, ARA290 given late did not change kidney inflammation, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeRenal inflammation, late treatment
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Late- or repetitive treatment did not affect inflammation or acute kidney injury.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with renal ischemia/reperfusion, late ARA290 treatment did not affect acute kidney injury.

    In plain wordsIn rats with kidney injury, ARA290 given late did not change acute kidney damage, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeAcute kidney injury, late treatment
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Late- or repetitive treatment did not affect inflammation or acute kidney injury.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In rats with renal ischemia/reperfusion, repetitive ARA290 treatment did not affect inflammation.

    In plain wordsIn rats with kidney injury, repeated ARA290 doses did not change kidney inflammation, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeRenal inflammation, repetitive treatment
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Late- or repetitive treatment did not affect inflammation or acute kidney injury.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with renal ischemia/reperfusion, repetitive ARA290 treatment did not affect acute kidney injury.

    In plain wordsIn rats with kidney injury, repeated ARA290 doses did not change acute kidney damage, compared with saline.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeAcute kidney injury, repetitive treatment
    Study

    ratn: not reported in source

    Renal ischemia/reperfusion injury
    Comparator
    Saline vehicle
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Late- or repetitive treatment did not affect inflammation or acute kidney injury.
    1 context sentence
    Summary · context
    Twenty-six male Lewis/HanHsd rats were exposed to unilateral ischemia for 30 minutes, with subsequent removal of the contralateral kidney. Post-reperfusion, ARA290 was administered early (one hour), late (four hours) or repetitive (one and four hours). Saline was used as vehicle treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.